Accessability Links

A targeted approach to cancer treatment

17 Jul 15 - 12:00AM Skills Alliance  | Carl Marotta blog

By Carl Marotta
CEO Skills Alliance


Skills Alliance are happy to announce a series of blogs focused on Oncology & the new treatments available for various types of cancer. In this mini-series we will briefly discuss various indications from lung through to pancreatic and how the use of nanotechnology, personalised medicine & immunotherapy are improving the chances of survival and quality of life.

Here is the first blog focused on lung cancer & immunotherapy.

Lung cancer is one of the most common forms of cancer, presenting with 1.6 million new cases each year.1 In fact more people die of lung cancer than of colon, breast and prostate cancers combined.2 In Europe alone, lung cancer is responsible for almost 270,000 deaths each year.3 

Advances in research and drug development is crucial to tackle such an aggressive and lethal cancer. Since lung cancer is more than one disease, distinct subtypes can be characterised by receptors that are frequently altered or overexpressed in cancer cells. One such molecular marker is epithelium growth factor receptor (EGFR). The prevalence of tumours harbouring EGFR mutations is between 10-15% in Caucasian and 40% in Asian non-small cell lung cancer (NSCLC) patients.4

ASCO recommends that if a doctor is thinking about giving an EGFR (tyrosine kinase inhibitor - TKI) to a patient with advanced NSCLC who hasn’t had chemotherapy before, the patient should be tested for tumour EGFR mutations to determine the most appropriate treatment. Mostly doctors believe that EGFR testing helps them move towards personalised medicine, rather than interpersonal chemotherapy treatment, where all patients take the same medicine.5

It is really important to remember that each person is different and their biology should be taken into consideration when deciding which treatment they should receive. The introduction of biologics for the treatment of cancer (immune-oncology) has enabled doctors to tailor treatments for each patient, and this therapy has demonstrated durable responses.5

In clinical trials, afatinib (Giotrif – Boehringer Ingelheim) has been shown to offer patients with NSCLC a significant delay in tumour progression, coupled with improvements in their lung cancer related symptoms (e.g. shortness of breath, cough and chest pain) and quality of life.6,7 Other drugs that have been used for the treatment of NSCLC with significant improvement in overall survival versus chemotherapy are gefitinib (Iressa – AztraZeneca) and erlotinib (Tarceva – Roche).
Therefore, early mutation testing for EGFR status is an important step in the treatment decision making, to give patients the opportunity to receive the appropriate personalised therapy from the start.

Immunotherapy is a relatively new area of medicine, and for cancer treatments it works by increasing the ability of the healthy cells to activate an immune response against the cancerous cells.  It has been demonstrated that there is a very vigorous immune response against tumours that can be activated using antibodies that block immune checkpoints. It can also be used in combinations with vaccines, or by taking this response out of the body and re-educating and re-engineering it with T-cells in the adoptive T-cell transfer approach. A good example of this is with anti-PD1 and anti-PD-L1 agents, which have been granted breakthrough status and are likely to become standard care for melanoma.8 What is really exciting is the fact that a prolonged immune response is triggered due to the immunologic memory.9

Immunotherapy for cancer stimulates immunologic memory, which may lead to a prolonged anti-tumour response.9

Scientists around the world have now observed several success stories in various areas of oncology using this method of treatment. Immunotherapy is here to stay and it will continue to make a significant impact in cancer treatment and patient care. This is both exciting and encouraging and one of several new breakthrough areas for treating cancer patients.

Having personally worked in life science executive staffing for the past 10+ years after a stint in industry, the last 24 – 36 months have been the most exciting I can recall. As a business, we have been fully focused on launch work for both start-up biotechnology and established pharmaceutical companies bringing new, innovative therapies to market. It’s a very exciting time to be part of the pharmaceutical industry with new diseases being cured and more lives being saved than ever before.

In my next blog I will discuss my thoughts and impressions on how established cancer treatments and chemotherapy drugs are being utilised by specialist oncology companies and being combined with new nanotechnology delivery systems. This is for me, one of the most exciting and impressive area. Companies like Baxalta and Celgene are at the heart of this with pancreatic cancer treatments focusing on a targeted approach to target cancer cells and not healthy cells.

For questions or to discuss any potential executive staffing projects across the EMEA or North America please do contact me either via email (, phone (+44207 233 6202) or Linked-in.


  1. Ferlay J et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. International Journal of Cancer. 2010; 127 2893-2917.

  2. American Cancer Society. What are the key statistics about lung cancer? Available at (Accessed July 2015).
  3. Malvezzi M et al. European cancer mortality predictions for the year 2013. Annals of Oncology, 2013.
  4. Jang, T.W. et al. 2009. EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung. The Korean Journal of Internal Medicine, March; 24(1), pp.48–54.
  5. Cancer net - (Accessed July 2015)
  6. Yang J, Hirsh V, Schuler M, et al. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations. J Clin Oncol 2013.
  7. Sequist L, Yang J, Yamamoto N, et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations. J Clin Oncol 2013.
  8. ESMO conference 2014 - (Accessed July 2015)
  9. Fight cancer immunotherapy - (Accessed July 2015)